Eupatilin Inhibits Reactive Oxygen Species Generation via Akt/NF-κB/MAPK Signaling Pathways in Particulate Matter-Exposed Human Bronchial Epithelial Cells

Dong Chang Lee 1, Jeong-Min Oh 2, Hyunsu Choi 2, Sung Won Kim 1, Soo Whan Kim 1, Byung Guk Kim 1, Jin Hee Cho 1, Joohyung Lee 1 2 and Ji-Sun Kim 1 *

1 Department of Otorhinolaryngology Head and Neck Surgery, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea; sayman@hanmail.net (D.C.L.); kswent@catholic.ac.kr (S.W.K.); kshent@catholic.ac.kr (S.W.K.); coolkim@catholic.ac.kr (B.G.K.); entcho@catholic.ac.kr (J.H.C.); fpsljh@gmail.com (J.L.)
2 Clinical Research Institute, Daejeon St. Mary’s Hospital, Daejeon 34943, Korea; 2013097@cmcdj.or.kr (J.-M.O.); peace420@cmcdj.or.kr (H.C.)
* Correspondence: skswltjs23@hanmail.net; Tel.: +82-2-2030-4560; Fax: +82-2-2030-2833

Abstract: Background: Eupatilin is an active flavon extracted from the Artemisia species and has properties such as antioxidant, anti-inflammatory, and anti-cancer. We examined the effect of eupatilin using fine particulate matter (FPM) and human bronchial epithelial cell line (BEAS-2B) to confirm the potential of eupatilin as a therapeutic agent for respiratory diseases caused by FPM. Methods: Reactive oxygen species (ROS) levels were checked by flow cytometry to identify if FPM and eupatilin affect ROS production. Western blotting was performed to identify the mechanism of action of eupatilin in FPM-exposed BEAS-2B cells. Results: When cells were exposed to FPM above 12.5 µg/mL concentration for 24 h, ROS production increased significantly compared to the control. When eupatilin was added to cells exposed to FPM, the ROS level decreased proportionally with the eupatilin dose. The phosphorylation of Akt, NF-κB p65, and p38 MAPK induced by FPM was significantly reduced by eupatilin, respectively. Conclusion: FPM cause respiratory disease by producing ROS in bronchial epithelial cells. Eupatilin has been shown to inhibit ROS production through altering signaling pathways. The ROS inhibiting property of eupatilin can be exploited in FPM induced respiratory disorders.

Keywords: eupatilin; particulate matter; ROS; bronchial epithelial cell

1. Introduction

There are well-documented serious adverse health effects of air pollution on human health. Particulate matter (PM), which is composed of organic compounds, metals, and dust particles, is known to be the cause of air pollution [1]. PM is classified according to the particle size. PM with a diameter of less than 10 µm is deposited mainly in the upper respiratory tract. Fine PM (FPM), which is less than 2.5 µm or less, enters the body through the bronchi by inhalation. Ultrafine particles (PM0.1) less than 0.1 µm can enter the body through the lungs and eventually travel to all organs. Acute and chronic exposure to PM has been shown in several studies to cause various inflammatory reactions in multiple human organs, especially to have a fatal effect on the respiratory system [2–5].

Respiratory epithelial cells control immunity in the body through various interactions with cells of the immune system and the production of defensive factors [6,7]. In particular, bronchial epithelial cells are at the forefront of defense against FPM [8]. Bronchial epithelial cells have been used in several studies that have identified the effects of FPM and the effects of therapeutic substances related to it [9,10].

In vitro test results have been reported on the mechanisms by which PM can cause respiratory disease. PM induces oxidative stress, cellular DNA damage, mitochondrial...
transformation, autophagy, and the production of various inflammatory cytokines in the cells of the respiratory system [11–14]. Substances that inhibit the mechanism of PM-induced damage can be carefully considered as a template for the development of therapeutic agents for PM-induced respiratory diseases.

Eupatilin (5,7-dihydroxy-3,4,6-trimethoxyflavone) is an active flavone extracted from Artemisia species and has been reported to have antioxidant, anti-inflammatory, anti-cancer, and neuroprotective effects [15–18]. Based on the literature, we hypothesized that eupatilin could reduce oxidative damage to respiratory cells caused by FPM. The purpose of our study was to confirm the potential of eupatilin as a therapeutic agent for respiratory diseases caused by FPM and to understand its mechanism. We examined reactive oxygen species (ROS) generation by FPM, the effect of eupatilin on it, and its mechanism of action using human bronchial epithelial cell lines (BEAS-2B).

2. Materials and Methods
2.1. Reagents

Fine atmospheric particulate matter NIST 2786, eupatilin, 5-(and 6)-carboxy-2′,7′-dichlorodihydrofluorescein diacetate (H2DCFDA), and Collagenase A were obtained from Sigma-Aldrich (St Louis, MO, USA). Antibodies against p38 mitogen-activated protein kinase (MAPK, #9212), phosphorylated p38 MAPK (#4511), Protein Kinase B (Akt, #9272), phosphorylated Akt (#9275), Nuclear factor kappa B (NF-κB) p65 (#8242), phosphorylated p65 (#3036), and Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH, #5174) were provided by Cell Signaling Technology (Danvers, MA, USA). An inhibitor of Akt (MK-2206) and an inhibitor of NF-κB p65 (BAY11-7082) were purchased from Sigma-Aldrich (St Louis, MO, USA). FPM was suspended in phosphate-buffered saline (PBS). Eupatilin and inhibitors were dissolved in dimethylsulfoxide (DMSO). DMSO alone had no observable effect at concentrations used (data not shown).

2.2. Cell Cultures

BEAS-2B cells were purchased from ATCC (Manassas, VA, USA). BEAS-2B cells were cultured in BEGM media with SingleQuot supplements kit additives (Lonza, Walkersville, MD, USA) on a tissue culture flask at an environment of 37 °C and less than 5% CO2. BEAS-2B cells were maintained at passages below 20 for all studies.

2.3. Cell Viability Assay

The viability of BEAS-2B cells was measured using the WST Assay Kit (DoGen, Seoul, Republic of Korea) to confirm the cytotoxicity of FPM and eupatilin. The WST assay is to measure the amount of viable cells using the function of the cellular mitochondrial dehydrogenase that the tetrazolium salt WST reduces to formazan, and the results are measured with a spectrophotometer. BEAS-2B cells were transferred to each well of a 96-well plate for 24 h (5 × 103 cells/well). After washing twice with PBS, serial concentration of FPM (0–50 µg/mL) and eupatilin (0–100 nM) were added and incubated for 24 h. After adding 10 µL of WST reagent and incubating the cells for an additional 2 h, the absorbance of each well was measured at 450 ± 20 nm in an ELISA reader (Bio-Rad Laboratories, Hercules, CA, USA) to confirm the cell viability (%).

2.4. Quantification of Intracellular ROS

BEAS-2B cells were first incubated for 24 h in a 60 mm dish (1 × 10⁵ cells/dish). After washing twice with ice-cold PBS, cells were added with serial concentrations of FPM (0–50 µg/mL) or eupatilin (0–100 nM). The process for detecting intracellular ROS was as follows. BEAS-2B cells were harvested and washed twice with PBS. The cells were then resuspended in Hanks’ Balanced Salt Solution (HBSS) with 10 µM of H2DCFDA. The cell suspension was incubated in the dark at 37 °C for 15 min, then rinsed 3 times with HBSS. The fluorescence intensity of the collected cells was measured using FACS Canto 2 (BD Biosciences, Franklin Lakes, NJ, USA).
2.5. Western Blotting

The cells were lysed in RIPA buffer (50 mM Tris-HCl pH 7.2, 150 mM NaCl, 1% NP-40, 0.1% sodium dodecyl sulfate, 0.5% sodium deoxycholate, 1 mM phenylmethylsulfonyl fluoride, 25 mM MgCl$_2$) containing a protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany). To measure the concentration of proteins, we used the bicinchoninic acid kit (Pierce, Rockford, IL, USA). In 10% sodium dodecyl sulfate-polyacrylamide gel, 20 µg of protein was separated by electrophoresis and transferred to a nitrocellulose membrane. The membrane was blocked in TBST (10 mM Tris-Cl, 150 mM NaCl, pH 8.0, 0.05% tween-20) containing 5% non-fat powdered milk. Then, after washing 3 times for 5 min each wash with TBST buffer, the membranes were incubated with primary antibodies (1:1000 dilution) overnight at 4ºC. After that, they were washed 3 times with TBST and incubated with anti-rabbit horseradish peroxidase-conjugated secondary antibodies (1:2000 dilution) for 1 h at room temperature. Labeled proteins were identified using enhanced chemiluminescent detection reagents (GE healthcare, Marlborough, MA, USA), and band intensities were analyzed with Image Lab software (Bio-Rad, Hercules, CA, USA).

2.6. Statistical Analyses

Data was analyzed using GraphPad Prism version 5 software (Graph-Pad, San Diego, CA, USA) of all experiments repeated at least 3 times. Statistical significance between means ± standard errors of the mean was investigated using one-way analysis of variance followed by Tukey’s post-test. $p < 0.05$ were considered statistically significant.

3. Result

3.1. Effects of FPM and Eupatilin on the Viability of BEAS-2B Cells

The effect on cell viability was determined by WST assay. BEAS-2B cells were incubated with serial concentrations of eupatilin or FPM for 24 h. Treatment with FPM (>12.5 µg/mL) significantly reduced the viability of BEAS-2B cells ($p < 0.001$) (Figure 1A). On the other hand, eupatilin treatment (>1 nM) significantly increased cell viability ($p < 0.01$). (Figure 1B). The decrease in cell viability due to FPM treatment of 12.5 µg/mL was attenuated by eupatilin, and this effect was statistically significant at concentrations of eupatilin above 10 nM (Figure 1C).

![Figure 1](image1.png)

Figure 1. Effects of FPM and eupatilin on BEAS-2B cell viability. (A) BEAS-2B cell viability after FPM treatment for 24 h. (B) BEAS-2B cell viability after treatment with eupatilin for 24 h. (C) BEAS-2B cell viability after treatment with eupatilin and FPM for 24 h. Three independent experiments were conducted. Each value in the graph presented as the mean ± SEM. ** $p < 0.01$ and *** $p < 0.001$ vs. control untreated group; # $p < 0.05$ and ## $p < 0.01$ vs. 12.5 µg/mL FPM. FPM, fine particulate matter; WST, water-soluble tetrazolium salts.

3.2. Opposite Effects of FPM and Eupatilin on ROS Generation in BEAS-2B Cells

To confirm whether FPM and eupatilin affected ROS generation, ROS levels were confirmed by flow cytometry after staining BEAS-2B cells with DCF-DA. At FPM treatment above 12.5 µg/mL concentration for 24 h, ROS production was significantly increased
compared to control ($p < 0.001$) (Figure 2A). ROS production in BEAS-2B cells decreased significantly of exposure to eupatilin (10 nM) compared with the controls ($p < 0.05$) (Figure 2B).
3.3. Eupatilin Reduces FPM-Induced ROS Production in BEAS-2B Cells

Flow cytometry was performed to evaluate the effect of eupatilin on FPM-induced ROS production. BEAS-2B cells were pretreated with various doses of eupatilin (0, 1, 10, or 100 nM), and then the cells were incubated in the present or absent of 12.5 µg/mL of FPM for 15 min. ROS levels were significantly increased in the FPM treatment group compared to the control untreated group ($p < 0.001$). In the group treated with FPM and eupatilin, ROS levels decreased proportionally to the dose of eupatilin. (Figure 2C). In particular, eupatilin treatment with a dose of 10 nM or more resulted in a statistically significant reduction compared to treatment with FPM alone.

3.4. FPM Induces Phosphorylation of Akt, p65, and p38 in BEAS-2B Cells

To identify the signaling pathways that FPM induced ROS production in BEAS-2B cells, phosphorylation of Akt, NF-κB p65, and p38 MAPK was examined by Western blotting. The expression levels of phosphorylated Akt, NF-κB p65, and p38 MAPK were significantly increased after 5 min exposure to FPM compared to each control group ($p < 0.05$) (Figure 3A–D).

3.5. Eupatilin Reduces Phosphorylation of Akt, p65, and p38 in FPM-Exposed BEAS-2B Cells

Western blotting was performed to confirm the mechanism of action of eupatilin in FPM-exposed BEAS-2B cells. The BEAS-2B cells were pretreated with 10 nM of eupatilin or DMSO for 24 h, and then the cells were incubated in the present or absent of 12.5 µg/mL of FPM for 15 min. After incubation, whole cell lysates were subjected to SDS-PAGE and blotted with Akt, p65, and p38 antibodies. The phosphorylation of Akt, NF-κB p65, and p38 MAPK induced by FPM was significantly reduced by eupatilin, respectively ($p < 0.05$) (Figure 3E–H).
3.6. Eupatilin as an Inhibitor of the Akt/NF-κB/MAPK Signaling Pathways in FPM-Exposed BEAS-2B Cells

Western blotting was performed by additional treatment with inhibitors of specific signals to confirm the relationship between Akt, p65, and p38, which are involved in the action of eupatilin. The BEAS-2B cells were pretreated with 10nM of eupatilin, 10 µM of MK-2206, and 10 µM of BAY11-7082 or DMSO for 24 h, and then the cells were incubated in the present or absent of 12.5 µg/mL of FPM for 15 min. After incubation, whole cell lysates were subjected to SDS-PAGE and blotted with Akt, p65 and p38 antibodies. Phosphorylation of NF-κB p65, p38 MAPK and Akt was inhibited when BEAS-2B cells exposed to FPM were co-cultured with MK-2206, which acts as an Akt inhibitor (Figure 4). This is a statistically significant inhibitory effect when compared to the group exposed only to FPM (p < 0.001). In BEAS-2B cells exposed to FPM after pretreatment with BAY11-7082 acting as an NF-κB inhibitor, NF-κB p65 as well as Akt and p38 MAPK were inhibited. In FPM-exposed BEAS-2B cells, eupatilin inhibited the activities of Akt, NF-κB p65, and p38 MAPK.
Figure 4. Effects of eupatilin, MK-2206 (Akt inhibitor), and BAY11-7082 (NF-κB inhibitor) on the FPM induced activation of Akt, p65, and p38 in BEAS-2B cells. The BEAS-2B cells were stimulated with FPM (12.5 µg/mL) with or without eupatilin (10 nM), MK-2206 (10 µM), and BAY11-7082 (10 µM of). (A) p-Akt, total Akt, p-p65, total p65, p-p38, and total p38 protein expression levels were determined by Western blot. (B) Density ratio of p-Akt to Akt. (C) Density ratios of p-p65 to p65. (D) Density ratios of p-p38 to p38. Three independent experiments were conducted. Each value of the graph represents the mean ± SEM. *p < 0.05 and **p < 0.001 vs. 0 µg/mL of FPM and 0 nM of eupatilin; ##p < 0.01 and ###p < 0.001 vs. 12.5 µg/mL of FPM. FPM: fine particulate matter; Akt: protein kinase B; GAPDH: Glyceraldehyde-3-Phosphate Dehydrogenase; SEM: standard error of the mean; MK-2206: Akt inhibitor; BAY11-7082: p65 inhibitor.

3.7. Inhibitory Effect of Eupatilin, MK-2206, and BAY11-7082 on ROS Products in BEAS-2B Cells

Flow cytometry was performed to confirm the effect of eupatilin, MK-2206, and BAY11-7082 on ROS production. BEAS-2B cells were pretreated with eupatilin (10 nM), MK-2206 (10 µM), and BAY11-7082 (10 µM) or DMSO as a control for 24 h, and then the cells were incubated in the present or absent of FPM (12.5 µg/mL) for 15 min. ROS levels were significantly reduced in each of the three groups pretreated with eupatilin or inhibitors compared to the group treated with FPM only (Figure 5).
In our results, FPM significantly produced ROS and induced phosphorylation of Akt, NF-κB p65, and p38 MAPK in human bronchial epithelial cells. Eupatilin significantly inhibited the ROS production and the phosphorylation of Akt, NF-κB p65, and p38 MAPK induced by FPM. MK-2206 as an Akt inhibitor and BAY11-7082 as an NF-κB inhibitor inhibited the phosphorylation of Akt, NF-κB p65, and p38 MAPK induced by FPM. Eupatilin also suppressed these signals activated by FPM.

Long- and short-term exposure of FPM to the respiratory system, which is a major entry channel into the body, has significant adverse health effects. It has been confirmed that it exacerbates chronic obstructive pulmonary disease (COPD) and asthma, and causes acute lung damage, resulting in an increase in the length of hospitalization and years of life loss [19–22]. Basic research has been conducted to identify the molecular mechanisms and therapeutic drugs for this. BEAS-2B cells have been widely used to describe the molecular mechanisms involved in the respiratory toxicity of FPM. FPM induced ROS production, pro-inflammatory cytokine production, autophagy, and cytotoxicity of immune cells through several signaling pathways in BEAS-2B cells [23–25].
Endogenous ROS generated during inflammatory reaction damages epithelial cells by oxidizing DNA, lipid, and protein. This is known as an important damage mechanism for respiratory diseases such as COPD and pulmonary fibrosis [26,27]. In a previous study, we confirmed that PM induces ROS production in human nasal fibroblasts that function immunologically in the upper respiratory tract [28]. In this study, ROS was induced by FPM in bronchial epithelial cells that play an important role in the immune control of the lower respiratory tract.

Eupatilin is known to have anti-inflammatory, antioxidant, and anti-cancer properties. There have been studies on the antioxidant role of eupatilin in epithelial cells of various organs [18,29]. As an example, there was an in vivo experiment confirming that eupatilin inhibited the production of ROS and inflammatory cytokines in acute lung injury induced by LPS [17]. As can be seen from our study results, the generation of ROS induced in bronchial epithelial cells due to FPM is inhibited by eupatilin, suggesting that eupatilin could be considered as a treatment for respiratory diseases caused by FPM.

Akt is a key protein in the Akt signaling pathway that promotes cell growth and survival. Urban PM is known to induce an inflammatory reaction by activating Akt in respiratory epithelial cells [30,31]. In particular, it is known that AKT acts on the generation of oxidative stress caused by FPM in respiratory epithelial cells [32]. Akt pathway induces the NF-κB signaling by stimulating the transactivation domain of p65 [33]. Transcription factor p65 is a subunit of the NF-κB family, an essential transcription factor complex for regulating DNA transcription, cytokine production, and cell survival. Excessive ROS generation activates the inhibitor of NF-κB (IκB) kinase, which degrades IκB and eventually releases transcription factors such as p65 and p50, leading to the production of inflammatory cytokines [34,35]. Several studies have reported that FPM induces inflammatory reactions in respiratory epithelial cells through the NF-κB pathway [36,37]. p38 MAPK is a class of MAPKs that is involved in cell differentiation, apoptosis, and autophagy. This MAPK pathway is activated by environmental stress and inflammatory stimulation, and this process is commonly known to coexist with the NF-κB pathway [38]. ROS phosphorylates p38 and induces apoptotic cell death [39]. In our results, phosphorylation of Akt, p65, and p38 was induced by FPM, and eupatilin inhibited it. For this reason, it was postulated that the Akt, NF-κB, and MAPK signaling pathways acted as the inhibitory mechanisms of eupatilin.

We confirmed that MK-2206, a selective Akt inhibitor, inhibited the phosphorylation of Akt, p65, and p38 induced by FPM. BAY11-7082, as an inhibitor of IκB kinase, inhibits the activation of NF-κB (IκB) kinase, which degrades IκB and eventually releases transcription factors such as p65 and p50, leading to the production of inflammatory cytokines [34,35]. Several studies have reported that FPM induces inflammatory reactions in respiratory epithelial cells through the NF-κB pathway [36,37]. p38 MAPK is a class of MAPKs that is involved in cell differentiation, apoptosis, and autophagy. This MAPK pathway is activated by environmental stress and inflammatory stimulation, and this process is commonly known to coexist with the NF-κB pathway [38]. ROS phosphorylates p38 and induces apoptotic cell death [39]. In our results, phosphorylation of Akt, p65, and p38 was induced by FPM, and eupatilin inhibited it. For this reason, it was postulated that the Akt, NF-κB, and MAPK signaling pathways acted as the inhibitory mechanisms of eupatilin.

5. Conclusions

FPM cause respiratory disease by producing ROS in bronchial epithelial cells. The Akt/NF-κB/MAPK signaling pathway is suggested to be a pathogenic mechanism for this process, and eupatilin could inhibit ROS production by inhibiting this mechanism. This is a meaningful result confirming the potential of eupatilin as a therapeutic agent at a time
when research on respiratory diseases caused by FPM is pouring out. Further experiments on the chemical properties of eupatilin and in vivo studies will bring us one step closer to the development of treatments for respiratory diseases caused by FPM.

**Author Contributions:** Conceptualization, D.C.L.; Methodology, J.-M.O., H.C., S.W.K. (Sung Won Kim), S.W.K. (Soo Whan Kim), B.G.K., J.H.C., J.L., and D.C.L.; Software, J.-M.O. and H.C.; Validation, S.W.K. (Sung Won Kim), S.W.K. (Soo Whan Kim), B.G.K., J.H.C., and J.L.; Formal analysis, S.W.K. (Sung Won Kim), S.W.K. (Soo Whan Kim), B.G.K., J.H.C., and J.L.; Data curation, J.-M.O. and H.C.; Writing—Original Draft Preparation, J.-S.K. and D.C.L.; Writing—Review and Editing, J.-S.K. and D.C.L.; Visualization, J.-M.O.; Supervision, J.-S.K. and D.C.L.; Project administration, D.C.L.; Funding Acquisition, D.C.L. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research is supported by the 2019 Research Support Program of the Catholic Medical Center Research Foundation, the Basic Science Research Program of the Korean Research Foundation (NRF-2017R1D1A1B03032768), the clinical research institution grant of the Catholic University of Daejeon St. Mary’s Hospital (CMCDJJ-P2019-005), and the Otorhinolaryngology Alumni Fund of the Catholic University of Korea.

**Institutional Review Board Statement:** The study protocol was approved by the Institutional Review Board of Daejeon St. Mary’s Hospital (IRB policy No. DC15TIS0022, 22 May 2020).

**Conflicts of Interest:** The authors declare that they have no financial interests or personal relationships could affect the work reported in this paper.

**References**

1. Mannucci, P.M.; Harari, S.; Martinelli, I.; Franchini, M. Effects on health of air pollution: A narrative review. *Intern. Emerg. Med.* 2015, **10**, 657–662. [CrossRef] [PubMed]

2. Cao, J.; Yang, C.; Li, J.; Chen, R.; Chen, B.; Gu, D.; Kan, H. Association between long-term exposure to outdoor air pollution and mortality in China: A cohort study. *J. Hazard. Mater.* 2011, **186**, 1594–1600. [CrossRef]

3. Dockery, D.W.; Pope, C.A.; Xu, X.; Spengler, J.D.; Ware, J.H.; Fay, M.E.; Ferris, B.G.; Speizer, F.E. An Association between Air Pollution and Mortality in Six U.S. Cities. *N. Engl. J. Med.* 1993, **329**, 1753–1759. [CrossRef] [PubMed]

4. Devries, R.; Kriebel, D.; Sama, S. Outdoor Air Pollution and COPD-Related Emergency Department Visits, Hospital Admissions, and Mortality: A Meta-Analysis. *COPD J. Chronic Obstr. Pulm. Dis.* 2017, **14**, 113–121. [CrossRef] [PubMed]

5. Kim, H.; Kim, H.; Park, Y.H.; Lee, J.T. Assessment of temporal variation for the risk of particulate matters on asthma hospitalization. *Environ. Res.* 2017, **156**, 542–550. [CrossRef] [PubMed]

6. Bals, R. Epithelial antimicrobial peptides in host defense against infection. *Respir. Res.* 2000, **1**, 5–50. [CrossRef]

7. Hiemstra, P. Epithelial antimicrobial peptides and proteins: Their role in host defence and inflammation. *Paediatr. Respir. Rev.* 2001, **2**, 306–310. [CrossRef] [PubMed]

8. Ru, Q.; Xiong, Q.; Chen, L.; Tian, X.; Yue, K.; Ma, B.; Liu, L.; Wu, R.; Xu, C.; Pi, M.; et al. Lipopolysaccharide accelerates fine particulate matter-induced cell apoptosis in human lung bronchial epithelial cells. *Int. Occup. Med. Environ. Health* 2017, **31**, 173–183. [CrossRef] [PubMed]

9. Jia, Y.; Li, X.; Nan, A.; Zhang, N.; Chen, L.; Zhou, H.; Zhang, H.; Qiu, M.; Zhu, J.; Ling, Y.; et al. Circular RNA 406961 interacts with ILF2 to regulate PM(2.5)-induced inflammatory responses in human bronchial epithelial cells via activation of STAT3/JNK pathways. *Environ. Int.* 2020, **141**, 105755. [CrossRef] [PubMed]

10. Pfeffer, P.E.; Lu, H.; Mann, E.H.; Chen, Y.-H.; Ho, T.-R.; Cousins, D.J.; Corrigan, C.; Kelly, F.J.; Mudway, I.S.; Hawrylowicz, C.M. Effects of vitamin D on inflammatory and oxidative stress responses of human bronchial epithelial cells exposed to particulate matter. *PLoS ONE* 2018, **13**, e0200040. [CrossRef] [PubMed]

11. Sotty, J.; Kluzu, J.; De Sousa, C.; Tardivel, M.; Anthérieu, S.; Alleman, L.-Y.; Canivet, L.; Perdrix, E.; Loyens, A.; Marchetti, P.; et al. Mitochondrial alterations triggered by repeated exposure to fine (PM2.5-0.18) and quasi-ultrafine (PM0.18) fractions of ambient particulate matter. *Environ. Int.* 2020, **142**, 105830. [CrossRef] [PubMed]

12. Risom, L.; Möller, P.; Loft, S. Oxidative stress-induced DNA damage by particulate air pollution. *Mutat. Res. Mol. Mech. Mutagen.* 2005, **592**, 119–137. [CrossRef] [PubMed]

13. Kim, J.-S.; Choi, H.; Oh, J.-M.; Kim, Y.-H.; Kim, S.W.; Kim, B.G.; Cho, J.H.; Lee, J.; Lee, D.C. Effect of fluticasone propionate on human nasal fibroblasts exposed to urban particulate matter. *Auris Nasus Larynx* 2020, **47**, 415–424. [CrossRef] [PubMed]

14. Sachdeva, K.; Do, D.C.; Zhang, Y.; Hu, X.; Chen, J.; Gao, P. Environmental Exposures and Asthma Development: Autophagy, Mitophagy, and Cellular Senescence. *Front. Immunol.* 2019, **10**, 2787. [CrossRef]

15. Yu, K.; Li, X.-M.; Xu, X.-L.; Zhang, R.-Y.; Cong, H.-L. Eupatilin protects against tumor necrosis factor-α-mediated inflammation inhuman umbilical vein endothelial cells. *Int. J. Clin. Exp. Med.* 2015, **8**, 22191–22197. [PubMed]
16. Lee, S.; Lee, M.; Kim, S.-H. Eupatilin inhibits H\textsubscript{2}O\textsubscript{2}-induced apoptotic cell death through inhibition of mitogen-activated protein kinases and nuclear factor-kappaB. *Food Chem. Toxicol.* 2008, 46, 2865–2870. [CrossRef]

17. Liu, H.; Hao, J.; Wu, C.; Liu, G.; Wang, X.; Yu, J.; Liu, Y.; Zhao, H. Eupatilin Alleviates Lipopolysaccharide-Induced Acute Lung Injury by Inhibiting Inflammation and Oxidative Stress. *Med. Sci. Monit.* 2019, 25, 8289–8296. [CrossRef] [PubMed]

18. Choi, E.-J.; Oh, H.-M.; Na, B.-R.; Ramesh, T.P.; Lee, H.-J.; Choi, C.-S.; Choi, S.-C.; Oh, T.-Y.; Chae, J.-R.; Kim, S.-W.; et al. Eupatilin Protects Gastric Epithelial Cells from Oxidative Damage and Down-Regulates Genes Responsible for the Cellular Oxidative Stress. *Pharm. Res.* 2008, 25, 1355–1364. [CrossRef]

19. Dominici, F.; Peng, R.D.; Bell, M.L.; Pham, L.; McDermott, A.; Zeger, S.L.; Samet, J.M. Fine Particulate Air Pollution and Hospital Admission for Cardiovascular and Respiratory Diseases. *JAMA* 2006, 295, 1127–1134. [CrossRef]

20. Zeng, Q.; Wu, Z.; Jiang, G.; Wu, X.; Li, P.; Ni, Y.; Xiong, X.; Wang, X.; Li, G.; Parasat, X. The association between ambient inhalable particulate matter and the disease burden of respiratory disease: An ecological study based on ten-year time series data in Tianjin, China. *Environ. Res.* 2017, 157, 71–77. [CrossRef]

21. Kim, S.-Y.; Peel, J.L.; Hannigan, M.P.; Dutton, S.J.; Sheppard, L.; Clark, M.L.; Vedal, S. The Temporal Lag Structure of Short-Term Associations of Fine Particulate Matter Chemical Constituents and Cardiovascular and Respiratory Hospitalizations. *Environ. Health Perspect.* 2012, 120, 1094–1099. [CrossRef] [PubMed]

22. Hoek, G.; Krishnan, R.M.; Beelen, R.; Peters, A.; Ostro, B.; Brunekreef, B.; Kaufman, J.D. Long-term air pollution exposure and cardio- respiratory mortality: A review. *Environ. Health* 2013, 12, 43. [CrossRef]

23. Long, F.; Jiang, H.; Yi, H.; Su, L.; Sun, J. Particulate matter 2.5 induced bronchial epithelial cell injury via activation of 5'-adenosine monophosphate-activated protein kinase-mediated autophagy. *J. Cell Biochem.* 2019, 120, 3294–3305. [CrossRef]

24. Ma, Q.-Y.; Huang, D.-Y.; Zhang, H.-J.; Wang, S.; Chen, X.-F. Exposure to particulate matter 2.5 (PM\textsubscript{2.5}) induced macrophage-dependent inflammation, characterized by increased Th1/Th17 cytokine secretion and cytotoxicity. *Int. Immunopharmacol.* 2017, 50, 139–145. [CrossRef] [PubMed]

25. Abbas, I.; Badran, G.; Verdin, A.; LeDoux, F.; Roumie, M.; Guidice, J.-M.L.; Courcot, D.; Garçon, G. In vitro evaluation of organic extractable matter from ambient PM\textsubscript{2.5} using human bronchial epithelial BEAS-2B cells: Cytotoxicity, oxidative stress, pro-inflammatory response, genotoxicity, and cell cycle deregulation. *Environ. Res.* 2019, 171, 510–522. [CrossRef] [PubMed]

26. Gonzalez-Gonzalez, F.J.; Chandel, N.S.; Jain, M.; Budginger, G.S. Reactive oxygen species as signaling molecules in the development of lung fibrosis. *Transl. Res.* 2017, 190, 61–68. [CrossRef]

27. Boukhenouna, S.; Wilson, M.A.; Bahmed, K.; Kosmider, B. Reactive Oxygen Species in Chronic Obstructive Pulmonary Disease. *Oxidative Med. Cell. Longev.* 2018, 2018, 1–9. [CrossRef]

28. Kim, J.-S.; Oh, J.-M.; Choi, H.; Kim, S.W.; Kim, B.G.; Cho, J.H.; Lee, J.; Lee, D.C. Activation of the Nrf2/HO-1 pathway by curcumin inhibits oxidative stress in human nasal fibroblasts exposed to urban particulate matter. *BMC Complement. Med. Ther.* 2020, 20, 101–108. [CrossRef]

29. Du, L.; Chen, J.; Xing, Y.-Q. Eupatilin prevents H\textsubscript{2}O\textsubscript{2}-induced oxidative stress and apoptosis in human retinal pigment epithelial cells. *Biomed. Pharmacother.* 2017, 85, 136–140. [CrossRef]

30. Watterson, T.L.; Hamilton, B.; Martin, R.S.; Coulombe, R.A. Urban particulate matter activates Akt in human lung cells. *Arch. Toxicol.* 2011, 86, 121–135. [CrossRef] [PubMed]

31. Lee, D.C.; Choi, H.; Oh, J.-M.; Lee, J.; Lee, H.Y.; Kang, J.Y. Urban particulate matter regulates tight junction proteins by inducing oxidative stress via the Akt signal pathway in human nasal epithelial cells. *Toxicol. Lett.* 2020, 333, 33–41. [CrossRef] [PubMed]

32. Liu, C.W.; Lee, T.L.; Chen, Y.C.; Liang, C.J.; Wang, S.H.; Lue, J.H.; Tsai, J.S.; Lee, S.W.; Chen, S.H.; Yang, Y.F.; et al. PM\textsubscript{2.5}-induced oxidative stress increases intercellular adhesion molecule-1 expression in lung epithelial cells through the IL-6/AKT/STAT3/NF-\textkappa B-dependent pathway. *Part. Fibre Toxicol.* 2018, 15, 4. [CrossRef]

33. Madrid, L.V.; Mayo, M.W.; Reuthler, J.Y.; Baldwin, A.S., Jr. Akt stimulates the transactivation potential of the RelA/p65 Subunit of NF-kappa B through utilization of the Ikappa B kinase and activation of the mitogen-activated protein kinase p38. *J. Biol. Chem.* 2001, 276, 18934–18940. [CrossRef] [PubMed]

34. Hoesel, B.; Schmid, J.A. The complexity of NF-\textkappa B signaling in inflammation and cancer. *Mol. Cancer* 2013, 12, 86. [CrossRef] [PubMed]

35. Perkins, N.D. Integrating cell-signalling pathways with NF-kappaB and IKK function. *Nat. Rev. Mol. Cell Biol.* 2007, 8, 49–62. [CrossRef] [PubMed]

36. Song, L.; Li, D.; Li, X.; Ma, L.; Bai, X.; Wen, Z.; Zhang, X.; Chen, D.; Peng, L. Exposure to PM\textsubscript{2.5} induces aberrant activation of NF-\textkappa B in human airway epithelial cells by downregulating miR-331 expression. *Environ. Toxicol. Pharmacol.* 2017, 50, 192–199. [CrossRef]

37. Wang, J.; Zhang, W.J.; Xiong, W.; Lu, W.H.; Zheng, H.Y.; Zhou, X.; Yuan, J. PM\textsubscript{2.5} stimulated the release of cytokines from BEAS-2B cells through activation of IKK/NF-\textkappa B pathway. *Hum. Exp. Toxicol.* 2019, 38, 311–320. [CrossRef]

38. Kyriakis, J.M.; Avruch, J. Mammalian MAPK Signal Transduction Pathways Activated by Stress and Inflammation: A 10-Year Update. *Physiol. Rev.* 2012, 92, 689–737. [CrossRef] [PubMed]
39. Ichijo, H.; Nishida, E.; Irie, K.; ten Dijke, P.; Saitoh, M.; Moriguchi, T.; Takagi, M.; Matsumoto, K.; Miyazono, K.; Gotoh, Y. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. *Science* 1997, 275, 90–94. [CrossRef]

40. Lee, J.; Rhee, M.H.; Kim, E.; Cho, J.Y. BAY 11-7082 Is a Broad-Spectrum Inhibitor with Anti-Inflammatory Activity against Multiple Targets. *Mediat. Inflamm.* 2012, 2012, 1–11. [CrossRef]